This study is in progress, not accepting new patients
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Robin Kate Kelley
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
- ID
- NCT02576509
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 743 people participating
- Last Updated